Piramal Pharma Strengthens Future Ready Operations with 22.6% Emissions Reduction, 41% Renewable Energy and Zero USFDA OAI Observations
Lowest-ever Scope 1 and Scope 2 emissions mark a milestone year in the Company's SBTi-approved decarbonisation journeyMUMBAI, India , Aug. 26, 2026 /PRNewswire/ -- Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceuticals company, today released its Sustainability Report 2025–26 , showcasing significant progress across its environmental, social and governance (ESG) priorities. Anchored by the theme "Advancing Innovation, Leveraging Sustainability," the report highlights how sustainability continues to be integrated into the Company's strategy, operations and innovation agenda while creating long-term value for patients, customers, communities and stakeholders.Key Highlights:Climate and Responsible Operations
Achieved a 22.6% reduction in Scope 1 and Scope 2 greenhouse gas emissions compared to the FY2022 baseline
Increased renewable energy usage to 41% of total energy consumption across operations
Recycled and reused 2.63 Lakh kilolitres of freshwater , and diverted 65% of total waste for recycling
